Jpmorgan Chase & CO Alkermes Plc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Alkermes Plc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 889,472 shares of ALKS stock, worth $31.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
889,472
Previous 359,510
147.41%
Holding current value
$31.9 Million
Previous $10.1 Million
154.23%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ALKS
# of Institutions
374Shares Held
173MCall Options Held
231KPut Options Held
158K-
Black Rock Inc. New York, NY29.1MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$664 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.3MShares$440 Million0.04% of portfolio
-
State Street Corp Boston, MA8.81MShares$316 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$271 Million3.55% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.9B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...